Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2015

Open Access 01-12-2015 | Research

Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review

Authors: Simon Zuber, Susan Weiß, Dieter Baaske, Michael Schöpe, Simon Stevens, Stephan Bodis, Daniel R Zwahlen

Published in: Radiation Oncology | Issue 1/2015

Login to get access

Abstract

Purpose

We are reporting the five-year biochemical control, toxicity profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early stage prostate cancer at a single institution.

Material and methods

Between April 2006 and December 2010, 169 men with early stage prostate cancer were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir + 2 ng/mL). Treatment-related morbidities, including urinary, rectal and sexual function, were measured, applying the International Prostate Symptom Score (IPSS), the 7-grade Quality of Life Scale (QoL) and medical status, the International Consultation on Incontinence Modular Questionnaire (ICIQ), the International Index of Erectile Function (IIEF-5) and the Common Terminology Criteria for Adverse Events (CTCAE v4.03). Seed migration and loss, dosimetric parameters and learning effects were also analyzed.

Results

Medium follow-up time was 50 months (range, 1–85 months). The five-year biochemical failure rate was 7%. Acute proctitis rates were 19% (grade 1) and 1% (grade 2), respectively. The overall incidence of incontinence was 19% (mild), 16% (moderate) and < 1% (severe). An increase in IPSS ≥ 5 points was detected in 59% of patients, with 38% regaining their baseline. Seed dislocation was found in 24% of patients and correlated with D90 and V100. A learning curve was found for seed migration, D90 and V100. QoL correlated with the general health condition of patient, incontinence symptoms and IPSS.

Conclusions

BT for early stage prostate cancer offers excellent five-year biochemical control with low toxicities. QoL aspects are favorable. A learning curve was detected for procedural aspects but its impact on patient relevant endpoints remains inconclusive.
Literature
1.
2.
Bestmann B, Loetters C, Diemer T, Weidner W, Küchler T, Rohde V. Prostate-specific symptoms of prostate cancer in a German general population. Prostate Cancer Prostatic Dis. 2007;10:52–9.CrossRefPubMed
3.
Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys. 2006;64:527–33.CrossRefPubMed
4.
Goldner G, Pötter R, Battermann JJ, Schmid MP, Kirisits C, Sljivic S, et al. Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients. Strahlenther Onkol. 2012;188:305–10.CrossRefPubMed
5.
Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31.CrossRefPubMed
6.
Horwitz EM. American Brachytherapy Society: ABS brachytherapy consensus guidelines. Brachytherapy. 2012;11:4–5.CrossRefPubMed
7.
Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, et al. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007;83(1):3–10. Epub 2007 Feb 26. PubMed PMID: 17321620.CrossRefPubMed
8.
Vikram B, Deore S, Beitler JJ, Sood B, Mullokandov E, Kapulsky A, et al. The relationship between dose heterogeneity (“hot” spots) and complications following high-dose rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;43:983–7.CrossRefPubMed
9.
Eshleman JS, Davis BJ, Pisansky TM, Wilson TM, Haddock MG, King BF, et al. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys. 2004;59:419–25.CrossRefPubMed
10.
Sugawara A, Nakashima J, Kunieda E, Nagata H, Mizuno R, Seki S, et al. Incidence of seed migration to the chest, abdomen, and pelvis after transperineal interstitial prostate brachytherapy with loose (125)I seeds. Radiat Oncol. 2011;6:130.CrossRefPubMedCentralPubMed
11.
Miura N, Kusuhara Y, Numata K, Shirato A, Hashine K, Sumiyoshi Y, et al. Radiation pneumonitis caused by a migrated brachytherapy seed lodged in the lung. Jpn J Clin Oncol. 2008;38:623–5.CrossRefPubMed
12.
Zhu AX, Wallner KE, Frivold GP, Ferry D, Jutzy KR, Foster GP. Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy. 2006;5:262–5.CrossRefPubMed
13.
Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, Karstens JH, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol. 2006;24:289–95.CrossRefPubMed
14.
Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 1998;160:1379–82.CrossRefPubMed
15.
Vijverberg PL, Blank LE, Dabhoiwala NF, de Reijke TM, Koedooder C, Hart AA, et al. Analysis of biopsy findings and implant quality following ultrasonically-guided 125I implantation for localised prostatic carcinoma. Br J Urol. 1993;72:470–7.CrossRefPubMed
16.
Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:121–8.CrossRefPubMed
17.
Gelblum DY, Potters L, Ashley R, Waldbaum R, Wang XH, Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67.CrossRefPubMed
18.
Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: morbidity and complications. Scand J Urol Nephrol Suppl. 1991;137:113–8.PubMed
19.
Nag S, Scaperoth DD, Badalament R, Hall SA, Burgers J. Transperineal palladium 103 prostate brachytherapy: analysis of morbidity and seed migration. Urology. 1995;45:87–92.CrossRefPubMed
20.
Beyer DC, Priestley JB. Biochemical disease-free survival following 125I prostate implantation. Int J Radiat Oncol Biol Phys. 1997;37:559–63.CrossRefPubMed
21.
Hu K, Wallner K. Clinical course of rectal bleeding following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 1998;41:263–265.22.CrossRefPubMed
22.
Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61. doi:10.1056/NEJMoa074311. PubMed PMID: 18354103.CrossRefPubMed
23.
Le Fur E, Malhaire JP, Baverez D, Delage F, Perrouin-Verbe MA, Schlurmann F, et al. Impact of learning curve and technical changes on dosimetry in low-dose brachytherapy for prostate cancer. Strahlenther Onkol. 2012;188:1091–5.CrossRefPubMed
24.
Liu H-W, Malkoske K, Sasaki D, Bews J, Demers A, Nugent Z, et al. The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team. Brachytherapy. 2010;9:202–7.CrossRefPubMed
25.
Keyes M, Schellenberg D, Moravan V, McKenzie M, Agranovich A, Pickles T, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys. 2006;64:825–34.CrossRefPubMed
26.
Taussky D, Moumdjian C, Larouche R, Béliveau-Nadeau D, Boudreau C, Hervieux Y, et al. Seed migration in prostate brachytherapy depends on experience and technique. Brachytherapy. 2012;11:452–6.CrossRefPubMed
27.
Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–57. discussion 1564.PubMed
28.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
29.
Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23:322–30.CrossRefPubMed
30.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–26.CrossRefPubMed
31.
Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003;56:1085–92.CrossRefPubMed
32.
Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. In Int J Radiat Oncol Biol Phys Volume. 2006;65:965–74.CrossRef
33.
34.
Stöckle M, Bussar-Maatz R. [Localised prostate cancer: the PREFERE trial]. Z Evid Fortbild Qual Gesundhwes. 2012;106:333–5. discussion 335.CrossRefPubMed
35.
Blasko JC, Wallner K, Grimm PD, Ragde H. Prostate specific antigen based disease control following ultrasound guided 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 1995;154:1096–9.CrossRefPubMed
36.
Brachman DG, Thomas T, Hilbe J, Beyer DC. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111–7.CrossRefPubMed
37.
Beyer DC, Thomas T, Hilbe J, Swenson V. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer. Brachytherapy. 2003;2:77–84.CrossRefPubMed
38.
Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–30.CrossRefPubMed
39.
Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M, et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin. 2004;20:607–17.CrossRefPubMed
40.
Keyes M, Miller S, Moravan V, Pickles T, Liu M, Spadinger I, et al. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up. Int J Radiat Oncol Biol Phys. 2009;75:649–55.CrossRefPubMed
41.
Stone NN, Stock RG. Complications following permanent prostate brachytherapy. Eur Urol. 2002;41:427–33.CrossRefPubMed
42.
Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys. 2001;50:335–41.CrossRefPubMed
43.
Reed DR, Wallner KE, Merrick GS, Arthurs S, Mueller A, Cavanagh W, et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy. 2007;6:129–34.CrossRefPubMed
44.
Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK. A dose–response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys. 1998;41:101–8.CrossRefPubMed
45.
Gómez-Iturriaga Piña A, Crook J, Borg J, Ma C. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy. Int J Radiat Oncol Biol Phys. 2010;78:422–7.CrossRefPubMed
46.
Taussky D, Austen L, Toi A, Yeung I, Williams T, Pearson S, et al. Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion. Int J Radiat Oncol Biol Phys. 2005;62:974–80.CrossRefPubMed
47.
Nag S, Bice W, DeWyngaert K, Prestidge B, Stock R, Yu Y. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys. 2000;46(1):221–30. Review. PubMed PMID: 10656396.CrossRefPubMed
48.
Beaulieu L, Evans D-AR, Aubin S, Angyalfi S, Husain S, Kay I, et al. Bypassing the learning curve in permanent seed implants using state-of-the-art technology. Int J Radiat Oncol Biol Phys. 2007;67:71–7.CrossRefPubMed
Metadata
Title
Iodine-125 seed brachytherapy for early stage prostate cancer: a single-institution review
Authors
Simon Zuber
Susan Weiß
Dieter Baaske
Michael Schöpe
Simon Stevens
Stephan Bodis
Daniel R Zwahlen
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2015
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-015-0349-0

Other articles of this Issue 1/2015

Radiation Oncology 1/2015 Go to the issue

Research

CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer

Research

Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy

Research

Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer

Research

Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?

Research

Bone density as a marker for local response to radiotherapy of spinal bone metastases in women with breast cancer: a retrospective analysis

Research

Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis